Richard Hawkins - SciClone Pharmaceuticals Independent Director
Director
Mr. Richard J. Hawkins is an Independent Director of SciClone Pharmaceuticals, Inc., since October 2004. Mr. Hawkins has served as a Director since October 2004. Since 2011, Mr. Hawkins was the President and Chief Executive Officer of Lumos Pharma, Inc., a privatelyheld company. Mr. Hawkins has served as the President and Chief Executive Officer of id2, Inc., a privatelyheld company since 1992, and as the Chairman and CEO of LabNow, Inc., a privatelyheld company he founded that develops labonachip sensor technology to be used in pointofcare diagnostic testing systems since 2003. From 1994 to 2000, Mr. Hawkins cofounded and served as Director at Corning BioPro, a protein contract manufacturing firm. From 1992 to 2000, Mr. Hawkins cofounded and served as Chairman of Sensus Drug Development, which developed and received regulatory approval for SOMAVERT, a growth hormone antagonist approved for the treatment of acromegaly and now marketed by Pfizer in both the United States and Europe. In 1982, Mr. Hawkins founded Pharmaco, a clinical research organization that in 1991 was merged with the predecessor of PPDPharmaco, one of the largest CROs in the world today. Mr. Hawkins has served as a member of the board of directors of Cytori Therapeutics, Inc. since 2007 since 2004.
Age | 66 |
Tenure | 20 years |
Phone | 650 358-3456 |
Web | www.sciclone.com |
SciClone Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.16 % which means that it generated a profit of $0.16 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.19 %, meaning that it created $0.19 on every $100 dollars invested by stockholders. SciClone Pharmaceuticals' management efficiency ratios could be used to measure how well SciClone Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.73 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. SciClone Pharmaceuticals has a current ratio of 8.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist SciClone Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, SciClone Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SciClone Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SciClone to invest in growth at high rates of return. When we think about SciClone Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
Theodore Sands | Albertsons Companies | 69 | |
James Sabala | Albertsons Companies | 60 | |
Edward Lippy | Hanover Foods | 78 | |
John Steele | Cincinnati Financial | 64 | |
Clayton Rohrbach | Hanover Foods | 88 | |
Sanjeev Dheer | Primerica | 61 | |
Gregory Bier | Cincinnati Financial | 71 | |
Tamara Ingram | Marsh McLennan Companies | 60 | |
Thomas Schiff | Cincinnati Financial | 70 | |
James Sturgill | Hanover Foods | 67 | |
Kenneth Lichtendahl | Cincinnati Financial | 69 | |
William Bahl | Cincinnati Financial | 66 | |
Lloyd Yates | Marsh McLennan Companies | 60 | |
Douglas Hunt | Albertsons Companies | 62 | |
Francis Kalitsi | Albertsons Companies | N/A | |
Oyewole Oyeleye | Albertsons Companies | N/A | |
Robert McCullough | Primerica | 74 | |
Deborah Hopkins | Marsh McLennan Companies | 66 | |
Douglas Skidmore | Cincinnati Financial | 55 | |
William McMullen | Cincinnati Financial | 57 | |
Rodney McMullen | Cincinnati Financial | 53 |
Management Performance
Return On Equity | 0.19 | |||
Return On Asset | 0.16 |
SciClone Pharmaceuticals Leadership Team
Elected by the shareholders, the SciClone Pharmaceuticals' board of directors comprises two types of representatives: SciClone Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SciClone. The board's role is to monitor SciClone Pharmaceuticals' management team and ensure that shareholders' interests are well served. SciClone Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SciClone Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Charles Meng, VP of Compliance and General Counsel | ||
Richard Hawkins, Independent Director | ||
Gregg Lapointe, Independent Director | ||
Hong Zhao, CEO of China Operations | ||
Wilson Cheung, CFO, Sr. VP of Fin. and Secretary | ||
Nancy Chang, Director | ||
Anthony Lapointe, Independent Director | ||
Lan Xie, VP of Fin. and CFO of China Operations | ||
Raymond Low, Vice President - Finance, Controller | ||
Robert King, Senior Vice President - Product Development and Supply Chain | ||
Simon Li, Independent Director | ||
Jon Saxe, Independent Chairman of the Board | ||
Friedhelm Blobel, CEO and President Executive Director and Member of Bus. Devel. Committee |
SciClone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SciClone Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.19 | |||
Return On Asset | 0.16 | |||
Profit Margin | 0.21 % | |||
Operating Margin | 25.82 % | |||
Current Valuation | 422 M | |||
Shares Outstanding | 52.19 M | |||
Shares Owned By Insiders | 10.03 % | |||
Shares Owned By Institutions | 79.96 % | |||
Number Of Shares Shorted | 1.21 M | |||
Price To Earning | 13.75 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in SciClone Stock
If you are still planning to invest in SciClone Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SciClone Pharmaceuticals' history and understand the potential risks before investing.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |